Exploring Morphine-Triggered PKC-Targets and Their Interaction with Signaling Pathways Leading to Pain via TrkA

Autor(es)

Pena, Darlene A. ^[1] ; Duarte, Mariana Lemos ^[2] ; Pramio, Dimitrius T. ^[1] ; Devi, Lakshmi A. ^[2] ; Schechtman, Deborah ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Chem Inst, Dept Biochem, BR-05508220 Sao Paulo - Brazil

^[2] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 - USA

• Tipo de documento: Artigo de Revisão
• Fonte: PROTEOMES; v. 6, n. 4 DEC 2018.
• Citações Web of Science: 2

Resumo

It is well accepted that treatment of chronic pain with morphine leads to opioid receptor (MOR) desensitization and the development of morphine tolerance. MOR activation by the selective peptide agonist, D-Ala2, N-MePhe4, Gly-ol]-enkephalin(DAMGO), leads to robust G protein receptor kinase activation, -arrestin recruitment, and subsequent receptor endocytosis, which does not occur in an activation by morphine. However, MOR activation by morphine induces receptor desensitization, in a Protein kinase C (PKC) dependent manner. PKC inhibitors have been reported to decrease receptor desensitization, reduce opiate tolerance, and increase analgesia. However, the exact role of PKC in these processes is not clearly delineated. The difficulties in establishing a particular role for PKC have been, in part, due to the lack of reagents that allow the selective identification of PKC targets. Recently, we generated a conformation state-specific anti-PKC antibody that preferentially recognizes the active state of this kinase. Using this antibody to selectively isolate PKC substrates and a proteomics strategy to establish the identity of the proteins, we examined the effect of morphine treatment on the PKC targets. We found an enhanced interaction of a number of proteins with active PKC, in the presence of morphine. In this article, we discuss the role of these proteins in PKC-mediated MOR desensitization and analgesia. In addition, we posit a role for some of these proteins in mediating pain by TrKA activation, via the activation of transient receptor potential cation channel subfamily V member 1 (TRPV1). Finally, we discuss how these new PKC interacting proteins and pathways could be targeted for the treatment of pain. (AU)

• Processo FAPESP: 15/21786-8 - Desenvolvimento, caracterização e aplicações de anticorpos específicos para as PKCs ativas
• Beneficiário: Deborah Schechtman
• Modalidade de apoio: Auxílio à Pesquisa - Regular